This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Dick, R. A. Articles by Kensler, T. W. Search for Related Content PubMed PubMed Citation Articles by Dick, R. A. Articles by Kensler, T. W.

NADPH Alkenal/One Oxidoreductase Activity Determines Sensitivity of Cancer Cells to the Chemotherapeutic Alkylating Agent Irofulven

¹ Department of Pharmacology and Molecular Sciences, Johns Hopkins School of Medicine, and² Division of Toxicological Sciences, Department of Environmental Health Sciences, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland

Illudins S and M are extremely cytotoxic products of the fungus Omphalotus illudens. They were evaluated as possible anticancer chemotherapeutic agents but displayed unfavorable therapeutic indices. Irofulven (6-hydroxymethylacylfulvene), a less toxic, synthetic derivative of illudin S, has proven very effective in many preclinical and clinical studies. It has been postulated that metabolism via hydrogenation of the 8,9-double bonds of these molecules would unmask the electrophilic, and thus, the toxic nature of their cyclopropyl moieties. Illudins S and M were found to be rapidly metabolized by NADPH-dependent alkenal/one oxidoreductase (AOR) with maximal rates of 115.9 and 44.1 µmol min^-1 mg^-1, and K_ms of 308 and 109 µM, respectively. Irofulven was reduced at a much slower rate: V_max 275 nmol min^-1 mg^-1 and K_m 145 µM. Human 293 cells transfected with an AOR overexpression vector were 100-fold more sensitive than control cells to irofulven, but displayed little differential sensitivity to illudin M. Addition of glutathione to the ,ß-unsaturated ketone moiety of illudin M, but not irofulven, occurred readily at physiological concentrations. Electrophilic intermediates of irofulven and illudin M that were activated by AOR were trapped with glutathione and identified by high performance liquid chromatography with tandem mass spectrometry. Samples of the 60 human tumor cell line panel used by the National Cancer Institute to evaluate potential chemotherapeutic compounds were assayed for AOR activity, which correlated positively with previously determined growth inhibitory measures for irofulven, but not illudin M or S. Collectively, these data indicate that bioactivation of irofulven by AOR plays a predominant role in its chemotherapeutic activity.

This article has been cited by other articles:

				A. Paci, K. Rezai, A. Deroussent, D. De Valeriola, M. Re, S. Weill, E. Cvitkovic, C. Kahatt, A. Shah, S. Waters, et al. Pharmacokinetics, Metabolism, and Routes of Excretion of Intravenous Irofulven in Patients with Advanced Solid Tumors Drug Metab. Dispos., November 1, 2006; 34(11): 1918 - 1926. [Abstract] [Full Text] [PDF]

				H. Liang, R. A. Salinas, B. Z. Leal, T. Kosakowska-Cholody, C. J. Michejda, S. J. Waters, T. S. Herman, J. M. Woynarowski, and B. A. Woynarowska Caspase-mediated apoptosis and caspase-independent cell death induced by irofulven in prostate cancer cells Mol. Cancer Ther., November 1, 2004; 3(11): 1385 - 1396. [Abstract] [Full Text] [PDF]

				R. A. Dick and T. W. Kensler The Catalytic and Kinetic Mechanisms of NADPH-dependent Alkenal/one Oxidoreductase J. Biol. Chem., April 23, 2004; 279(17): 17269 - 17277. [Abstract] [Full Text] [PDF]